Deadly snakes 'milked' to
create potent new anti-venom
Send a link to a friend
[April 03, 2015]
By Mathew Stock
LIVERPOOL, ENGLAND / KADUNA, NIGERIA - A
new anti-venom to treat victims of potentially deadly snake bites in
sub-Saharan Africa is just a few years away from reality, according to
scientists at the Liverpool School of Tropical Medicine (LSTM). They aim
to create a potent new anti-venom that can be stored safely at room
temperature, without the need for refrigeration.
|
Dr. Robert Harrison is leading the research at LSTM's Alistair Reid
Venom Research Unit, where he has collected 21 species - 450 animals
in total - of sub-Saharan Africa's most deadly snakes. Harrison and
his team have been extracting venom from the reptiles, using a
process known as 'milking', to concoct a new anti-venom that he
hopes will prevent the deaths and severe injuries of snake bite
victims.
"32,000 people are dying from snake bite every year in sub-Saharan
Africa. But it's not only that; other people who survive the bite -
about 100,000 of them - are living with severe disabled limbs or
legs, just really very disabling conditions," said Harrison.
He added that the impact on communities can be particularly severe
if a snake bite renders a family's main bread-winner unable to work:
"People are exposed to snakebite by whatever they're doing and
wherever they're doing it. And what it does do is affect these
people dramatically, because the loss of the main income earner for
instance because his arm can no longer function or he's had his leg
amputated as a result of snakebite. Or, god forbid, he dies from
snakebite then you can see how massively that would affect this tiny
little family unit that is living on probably less than a dollar a
day."
Anti-venoms are made by first 'milking' the venom from a snake
before injecting it in low doses into a horse or sheep. The animal
doesn't become ill, but the venom induces an immune response that
produces anti-bodies in the animal. These anti-bodies are then
extracted from the animal's blood to create anti-venom.
In rural areas of sub-Saharan Africa where people are exposed to
various species of deadly snakes, the current treatment involves a
broad-spectrum anti-venom to cover all the snake species that could
be responsible. But the current method for producing anti-venoms
means the animals make only a small amount of anti-body to any one
species; resulting in a weak anti-venom. Patients are therefore
having to be treated with multiple vials; carrying an increased risk
of side-effects and making the treatment largely unaffordable to
rural subsistence farmers. According to the UK's Medical Research
Council, a single vial of the most effective broad-spectrum
anti-venom currently costs about $140 USD per vial, and because
several vials are needed to achieve a cure it can cost over $500 USD
per treatment; an insurmountable cost for people who often earn less
that $1 USD a day.
[to top of second column] |
However, the research team at LSTM plans to vastly improve the
potency of broad-spectrum anti-venom using an innovative new
technique they've dubbed 'antivenomics', which targets unique
proteins in a particular snake species' venom. This, they say, will
significantly expand the effectiveness of the anti-venom to cover
all the poisonous snakes of sub-Saharan Africa.
"So what we're going to try and do is take our existing anti-venom
which we made for Nigeria and has been used in Nigeria; which is
effective, and it's cheap and it's safe. Now we're going to make it
more effective against all the other snakes of sub-Saharan Africa.
And we're going to do that by identifying the proteins that are
unique to all the other species. And taking these unique proteins.
i.e. different from the Source Scale Viper, the Puff Adder or the
Spitting Cobra, and add that to the venoms of the original three,"
explained Harrison.
The anti-venom will be manufactured using a more cost-effective
system developed in Costa Rica, reducing costs by up to three
quarters and making it more affordable to rural African communities.
The current need for anti-venoms to be refrigerated throughout their
manufacture and storage is a further limitation that they hope to
overcome. Harrison's team plans to test a series of special
molecules added to the anti-venom during creation to increase its
stability at ambient temperatures, with the aim of it still being
effective after at least a year stored at room temperature.
"And at the end of three-and-a-half, four years now; so 2018, July
2018 - we will do the ultimate test of whether this new anti-venom,
when it's stored at room temperature for at least a year, is
effective against all the snakes of sub-Saharan Africa."
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
|